Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Inhibrx, Inc. (Nasdaq: INBX) announced interim results from a Phase 1 clinical trial for INBRX-101, a recombinant human AAT-Fc fusion protein aimed at treating alpha-1 antitrypsin deficiency (AATD). The study involved 21 patients with no severe adverse events reported, and only mild to moderate drug-related effects. Dose-dependent increases in AAT levels were observed, with promising results indicating the potential for monthly dosing compared to the current standard of care requiring 52 infusions annually. Further data from multiple ascending doses is expected in early 2022.
Inhibrx, Inc. (Nasdaq: INBX) will host a live webcast on October 12, 2021, at 5:30 a.m. PT to present interim results from its Phase 1 clinical trial of INBRX-101, a treatment for alpha-1 antitrypsin deficiency (AATD). AATD affects approximately 100,000 patients in the U.S. and leads to severe lung function loss. INBRX-101 is designed for monthly dosing, addressing shortcomings of current weekly plasma-derived treatments. Further details and results will be available on Inhibrx's website following the presentation.
Inhibrx, a clinical-stage biotechnology company (NASDAQ: INBX), announced its participation in the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. Pacific Time. This virtual presentation will showcase its novel biologic therapeutic candidates in oncology and orphan diseases, utilizing its proprietary sdAb platform. Attendees can access the live webcast through Inhibrx's investor website, which will remain available for 60 days post-event. The company collaborates with major biotech firms, enhancing its research capabilities.
Inhibrx, Inc. (Nasdaq: INBX) reported its financial results for Q2 2021, showing cash and cash equivalents of $125.7 million, a slight decrease from $128.7 million at year-end 2020. R&D expenses decreased to $17.9 million, down from $19.0 million in Q2 2020, while G&A expenses rose to $2.9 million from $1.5 million. The company recorded a net loss of $20.7 million ($0.55 per share), compared to a net loss of $17.9 million ($0.99 per share) in the same quarter last year. The financial report reflects ongoing development in its clinical programs.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a potential registration-enabling Phase 2 study of INBRX-109 for chondrosarcoma, an orphan bone cancer with no approved treatments. The drug has shown promising results in an ongoing Phase 1 trial with disease control in 87.5% of patients. An additional loan agreement with Oxford Finance was amended, providing $40M in capital. The FDA granted Fast Track designation to INBRX-109 in January 2021. The new Phase 2 trial aims to evaluate the drug's efficacy through progression-free survival metrics.
Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology firm, will present at two upcoming virtual investor conferences: the Jefferies Healthcare Conference on June 2 at 12:30 p.m. PT and the JMP Securities Life Sciences Conference on June 17 at 8:00 a.m. PT. Live webcasts of these presentations can be accessed through the investor section of Inhibrx's website and will remain available for 60 days post-event. The company focuses on developing biologic therapeutic candidates for oncology and orphan diseases, utilizing advanced protein engineering techniques.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q1 2021 financial results on May 13, 2021. The company had cash and cash equivalents of $108 million, a decrease from $128.7 million at the end of 2020. R&D expenses dropped to $16.4 million, while G&A expenses rose to $3 million due to increased personnel costs. The net loss for the quarter was $19.3 million or $0.51 per share, an improvement from $20.1 million or $1.11 per share in Q1 2020. Inhibrx is progressing with its four clinical programs and expects data from all by year-end.
Inhibrx, Inc. (Nasdaq: INBX) announced its fourth quarter and fiscal year 2020 financial results, highlighting a transformative year with advancements in four clinical programs. The Phase 1 study of INBRX-105 showed a maximum tolerated dose of 1 mg/kg, with 44% of evaluable patients achieving stable disease. Cash and cash equivalents grew significantly to $128.7 million at year-end. However, the company reported a net loss of $76.1 million for the fiscal year, worsening from a net loss of $51.4 million in 2019.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Guggenheim Healthcare Talks: 2021 Oncology Days, scheduled for February 12, 2021, at 2 p.m. Pacific Time. The presentation will be webcast live, accessible via the investor section of the Inhibrx website, and available for 60 days post-event. Inhibrx is focused on developing a pipeline of novel biologic therapies for oncology and orphan diseases, utilizing its proprietary sdAb platform and collaborating with companies like bluebird bio and Bristol-Myers Squibb.
Inhibrx, a clinical-stage biotechnology company, announced that the FDA granted Fast Track designation to INBRX-109 for treating patients with unresectable or metastatic conventional chondrosarcoma. This innovative therapeutic candidate is designed to induce tumor-selective programmed cell death through death receptor 5 (DR5). The designation facilitates the development and review process of drugs for serious conditions. A Phase 2 study of INBRX-109 is planned for mid-2021, aiming to demonstrate efficacy in enhancing patient outcomes where no approved therapies currently exist.